1-2 of 2
Jamie Koprivnikar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study

Clinical Trials & Observations
Jessica K. Altman, Tsila Zuckerman, Jamie Koprivnikar, James McCloskey, Vamsi Kota, Michael Keng, Olga Frankfurt, Yasmin Abaza, Dale L. Bixby, Ashkan Emadi, Micah Burch, Bhavana Bhatnagar, Selina M. Luger, Mary-Elizabeth Percival, Ofir Wolach, Michael Craig, Chezi Ganzel, Gail Roboz, Itai Levi, Anna Gourevitch, Liat Flaishon, Shoshi Tessler, Chen Blumberg, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7494–7500.
https://doi.org/10.1182/bloodadvances.2023010943
Published: 2023
Journal Articles

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Clinical Trials & Observations
Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H. Al Ali, Eric Padron, David A. Sallman, Rami S. Komrokji, Aaron D. Goldberg
Journal: Blood Advances
Blood Adv (2020) 4 (13): 2866–2870.
https://doi.org/10.1182/bloodadvances.2020001482
Published: 2020
Includes: Supplemental data